A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)

Summary

The LYNX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics and biomarkers in children with Duchenne muscular dystrophy including a randomized, double-blind, placebo-controlled part A, followed by an open-label part B.

Timeline

Start

2022-10-24

Primary completion

2027-01

Completion

2027-01

Drugs

Indications